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a  b  s  t  r  a  c  t
6,7-Dihydroxycoumarin  (6,7-HC)  (aesculetin)  is  a natural  and  synthetic  coumarin  deriva-
tive of  great  interest  for use  by  humans  due  to their  potent  antioxidant  properties.
Considering  that  there  are  no  reports  that  assess  the in  vivo  genetic  toxicity  of  6,7-HC,
the  aim  of the present  study  was  to investigate  its genotoxic  potential  in  terms  of  DNA
damage  in  peripheral  blood,  liver,  bone  marrow  and  testicular  cells  of  Swiss  albino  mice
by the comet  assay,  and  its clastogenic/aneugenic  potential  in  bone  marrow  cells  using
the  micronucleus  test.  In addition,  the ability  of 6,7-HC  to modulate  the  genotoxic  effects
induced  by doxorubicin  (DXR)  was  also  preliminarily  evaluated.  Cytotoxicity  was  assessed
by scoring  polychromatic  (PCE)  and normochromatic  (NCE)  erythrocytes’  ratio.  The  test
compound  was  administered  orally  at doses  of 25, 50 and  500  mg  kg−1 isolated  and  also
simultaneously  to DXR  (80  mg  kg−1). The  results  showed  that 6,7-HC  did  not  induce  sig-Micronucleus test niﬁcant  DNA  damage  in  any  of  the analyzed  cells,  and  also did  not  show  any  signiﬁcant
increase  in  micronucleated  PCE  at the  three  tested  doses.  The  PCE/NCE  ratio  indicated  no
cytotoxicity.  Moreover,  the  extent  of DNA damage  induced  by  DXR  decreased  signiﬁcantly
only  in peripheral  blood  and  testicular  cells,  and  only  at the  lowest  dose  of  6,7-HC.
rs.  Publ
Y-NC-N© 2015  The  Autho
the  CC  B
1. Introduction
Coumarins are a large class of heterocyclic molecules
found in plants as secondary metabolites, mainly in
the fruits, seeds, roots, and leaves [1]. More than 1300
coumarins have been identiﬁed considering plants, bacte-
ria, and fungi [38]. Naturally occurring coumarins present
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a diverse range of pharmacologic/toxicologic proper-
ties, that include furanocoumarin-induced photoxicity
[2], antimicrobial [3], cytochrome P450 3A4 modulation
[4], cancer cell cytotoxicity [5], and anticarcinogene-
sis/chemoprevention of cancer [6–12].
The structure of coumarins could bind transition metal
ion such as Fe(III), and thus inhibit hydroxyl radical and
hydrogen peroxide formation produced by Fenton’s reac-
tions. Furthermore, their hydroxyl functions are potent H+donors for free radical acceptors due to electron delocaliza-
tion across the molecule [13]. Thus, coumarin derivatives
could be potent reactive oxygen species (ROS) scavengers
and metal chelating agents.
 access article under the CC BY-NC-ND license (http://creativecommons.
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Coumarin derivative molecules (or coumarin metabo-
ites) are naturally generated by the metabolism of
oumarin in the cell, and based on the coumarin chemi-
al structure system (ring) have been synthesized utilizing
nnovative synthetic techniques. It has been found that
hese derivatives present numerous therapeutic applica-
ions as: antitumor and anti-HIV therapy [14,15], central
ervous system stimulants [16], anti-inﬂammatory [17],
ntibacterials [18], and anticoagulants [19], among oth-
rs. Hydroxycoumarins present powerful chain-breaking
ntioxidants and can prevent free radical injury by scav-
nging reactive oxygen species [20]. This is the case of the
oumarin metabolite 6,7-dihydroxycoumarin (aesculetin),
hich may  be formed naturally in small quantities or
urchased commercially by synthetic techniques [21,39].
ince some coumarin derivatives can present adverse
ffects such as mild nausea, diarrhea, hepatotoxicity, and
ytotoxicity when used in certain amounts [22–25], a care-
ul evaluation of its genetic toxicity potential is necessary.
There are few studies evaluating the genetic tox-
city of natural and synthetic coumarin derivatives in
he literature. 4-Methylesculetin was evaluated in vitro
nd in vivo and all endpoints investigated showed that
his synthetic coumarin derivative had no mutagenic or
enotoxic effects. However, cytotoxicity at high concen-
rations was observed [26,27]. 6,7-Dihydroxycoumarin had
ts preliminary genetic toxicity studied only in vitro, and
almonella/microsome, comet and micronucleus assays
howed that this natural coumarin derivative did not
resent mutagenic, genotoxic or clastogenic/aneugenic
ction [27].
Most of the incurable and chronic diseases are the out-
omes of an overload of free radical attacks in the human
ystem resulting in an oxidative stress-like condition, and
NA and protein-like macro-molecules constitute vulner-
ble targets for free radical attack [28]. 6,7-HC, due to the
resence of two hydroxyl moieties on its benzene rings,
ffect the formation and scavenging of reactive oxygen
pecies (ROS) and inﬂuence free radical-mediated oxida-
ive damage, and is being considered one of the most
ffective antioxidant coumarins [21], and for this reason,
as the potential to be used by humans as an antioxidant,
rotecting against DNA damage, cancer and aging.
National and international regulatory agencies recom-
end the in vivo mammalian assessment of genotoxic-
ty/mutagenicity of any agent with therapeutic potential
or humans [37,40]. Considering this, and that the use of
,7-HC could promote human health, the present study
as performed to investigate for the ﬁrst time, the in vivo
enotoxic potential of 6,7-HC in peripheral blood, liver,
one marrow and testicular cells of mice, by the comet and
icronucleus tests. In addition, the possible antigenotox-
city of 6,7-HC on doxorubicin-induced DNA damage was
reliminarily assessed.
. Materials and methods.1. Chemicals
The 6,7-dihydroxycoumarin (6,7-HC) (Fig. 1) used in
he experiments was obtained from Sigma–Aldrich (Cat.Fig. 1. Chemical structure of 6,7-dihydroxycoumarin (aesculetin).
no. 24,657-3, CAS: 305-01-1, 98% purity) and solubilized
in sunﬂower oil. Doxorubicin (DXR) (IMA S.A.I.C. Labora-
tories) was used as the positive control substance due to
its potential as DNA damaging agent in the comet assay
and micronucleus test using Swiss mice. The other main
chemicals were obtained from the following suppliers:
normal melting point (NMP) agarose (Cat. no. 15510-019
– Invitrogen), low melting point (LMP) agarose (Cat. no.
15517-014 – Invitrogen), sodium salt N-lauroyl sarcosi-
nate (L-5125 – Sigma) and ethylenediaminetetraacetic acid
(EDTA – Merck).
2.2. Animals and treatments
The experiments were carried out using 12-week-old
male Swiss albino mice (Mus musculus), weighing 25–30 g.
The animals were acquired from the Universidade Estad-
ual Paulista (UNESP), Botucatu, São Paulo State, Brazil,
and housed in polyethylene boxes in a climate-controlled
environment (25 ± 4 ◦C, 55 ± 5% humidity) with a 12 h
light/dark cycle (7:00 am to 7:00 pm). Food (Nuvilab CR1,
Nuvital) and water were available ad libitum.  The mice
were divided into 8 experimental groups of 11 animals
each. 6,7-HC was  dissolved in sunﬂower oil and adminis-
tered in a single dose of 0.3 mL  by gavage at concentrations
of 25, 50 and 500 mg/kg body weight. In this procedure,
each animal was  weighed individually and then the calcu-
lated dose was solubilized in 0.3 mL  of the vehicle being
administered. These doses were selected based on our pre-
liminary acute toxic studies in mice, which was  higher than
500 mg/kg. The negative control group received sunﬂower
oil by gavage, and the positive control group received an
intraperitoneal injection of doxorubicin (DXR) at 80 mg/kg
body weight. Simultaneous treatments for antigenotoxic
assessment were carried out by administering the three
selected extract doses and then DXR 1 h later. The animals
used in this study were sacriﬁced by cervical dislocation
without anesthesia, to avoid possible alterations in the DNA
damage analysis. The Animal Bioethics Committee of the
Faculdade de Medicina de Marília (CEP/FAMEMA, Marília,
São Paulo state, Brazil) approved the present study on 14
April 2010 (protocol number 085/10), in accordance with
federal government legislations on animal care.
2.3. Comet assay
The comet assay (or single cell gel electrophoresis
(SCGE)) was  carried out by the method described by Speit
and Hartmann [29] and reviewed by Burlinson et al. [30].
Peripheral blood samples from the tail vein were obtained
from six Swiss mice of each group, at 4 and 24 h after
treatment and before euthanasia. After euthanasia, liver,
bone marrow and testicular cell samples were collected
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and washed in saline solution in an ice bath. A small portion
of each type (about 4 mm in diameter) was transferred to a
Petri dish containing 4 mL  phosphate buffer solution (PBS,
pH 7.4) and then gently homogenized with a small pair
of tweezers and a syringe to remove any clumps of cells.
The trypan dye exclusion method was used to determine
cell viability immediately before the comet assay; viabil-
ity was above 80% for all cell types and for all treatments.
Another aliquot (20 l) of each cell types from each animal
was mixed with 120 L of 0.5% low melting point agarose
at 37 ◦C, and rapidly spread onto two microscope slides per
animal, pre-coated with 1.5% normal melting point agarose.
The slides were coverslipped and allowed to gel at 4 ◦C for
20 min. The coverslips were gently removed and the slides
were then immersed in cold, freshly prepared lysing solu-
tion consisting of 89 mL  of a stock solution (2.5 M NaCl,
100 mM EDTA, 10 mM Tris, pH set to 10.0 with ∼8 g solid
NaOH, 890 mL  of distilled water and 1% sodium lauryl sar-
cosine), plus 1 mL  of Triton X-100 (Merck) and 10 mL  of
dimethyl sulfoxide (Merck). The slides, which were pro-
tected from light, were allowed to stand at 4 ◦C for 1 h
and then placed in the gel box, positioned at the anode
end, and left in a high pH (>13) electrophoresis buffer
(300 mM  NaOH-1 mM EDTA, prepared from a stock solu-
tion of 10 N NaOH and 200 mM,  pH 10.0, EDTA) at 4 ◦C for
20 min  prior to electrophoresis, to allow DNA unwinding.
The electrophoresis run was carried out in an ice bath (4 ◦C)
for 20 min  at 300 mA  and 25 V (0.722 V cm−1). The slides
were then submerged in a neutralization buffer (0.4 M
Tris–HCl, pH 7.5) for 15 min, dried at room temperature
and ﬁxed in 100% ethanol for 10 min. The slides were dried
and stored overnight or longer, before staining. For the
staining process, the slides were brieﬂy rinsed in distilled
water, covered with 30 L of 1× ethidium bromide staining
solution prepared from a 10× stock (200 g/mL) and cover-
slipped. The material was evaluated immediately at 400×
magniﬁcation, using a ﬂuorescence microscope (Olympus
BX 50) with a 515–560 nm excitation ﬁlter and a 590 nm
barrier ﬁlter. Only individual nucleoids were scored.
The extent and distribution of DNA damage indicated
by the SCGE assay was evaluated by examining at least 100
randomly selected and non-overlapping cells (50 cells per
coded slide) per animal in a blind analysis (six mice per
group). These cells were scored visually, according to tail
size, into the following four classes: class 0 – no tail; class 1
– tail shorter than the diameter of the head (nucleus); class
2 – tail length 1–2 times the diameter of the head; and class
3 – tail length more than twice the diameter of the head.
Comets with no heads, with nearly all of the DNA in the
tail or with a very wide tail, were being excluded from the
evaluation because they probably represented dead cells
[31]. The total score for 100 comets, which ranged from
0 (all undamaged) to 300 (all maximally damaged), was
obtained by multiplying the number of cells in each class
by the damage class.
2.4. Micronucleus testThe assay was carried out following standard protocols
as recommended by Schmid [41] and Maistro [32]. Five of
the same six male mice of each group used in the cometeports 2 (2015) 268–274
assay were sacriﬁced 24 h after treatment and the other
ﬁve animals were sacriﬁced 48 h after extract treatment (10
mice per group). The bone marrow from the femur of the
other mice was  ﬂushed out using 2 mL  of saline (0.9% NaCl)
and centrifuged at 1000 rev./min for 7 min. The supernatant
was  discarded. Four drops of formaldehyde (4%) was  added
to preserve the cell cytoplasm and smears were made on
slides. The slides were coded for a “blind” analysis, ﬁxed
with methanol and stained with Giemsa. For the analysis of
the micronucleated cells, 2000 polychromatic erythrocytes
(PCE) per animal were scored to determine the clasto-
genic/aneugenic property of the extract. To detect possible
cytotoxic effects, the PCE/NCE (normochromatic erythro-
cytes) ratio in 200 erythrocytes/animal was  calculated [33].
The cells were blindly scored using a light microscope
at 1000× magniﬁcation. The mean number of micronu-
cleated polychromatic erythrocytes (MNPCE) in individual
mice was  used as the experimental unit, with variability
(standard deviation) based on differences among animals
within the same group.
2.5. Modulation of genotoxic activity
The percentage change of genotoxic (observed by the
comet assay) agent-induced damage by 6,7-HC was calcu-
lated according to Waters et al. [34], using the following
formula:
% Change = A  − B
A − C × 100
where A corresponds to the score mean observed in
the treatment with CPA (positive control), B corresponds
to score mean observed in the antigenotoxic treatment
(extract plus DXR) and C corresponds to the score mean
in the control.
2.6. Statistical analysis
All data are expressed as the mean ± standard deviation
(n = 6/group in the comet assay; n = 5 for each time sample
in the MN  test). After verifying for normal distribution (nor-
mality test KS performed using GraphPad Instat® software),
the data obtained from the comet assay were submitted
to analysis of variance (ANOVA) and the Tukey–Kramer
multiple comparison test, and the data obtained from the
micronucleus assay were submitted to the analysis of vari-
ance test (ANOVA) with linear regression, both using the
GraphPad Prism 5 software (version 3.01). The results were
considered statistically signiﬁcant at P < 0.05.
3. Results
No distinctive toxic clinical signs, deaths or morbidity
were observed in the treated animals after 6,7-HC treat-
ments. DNA damage was  evaluated in blood leukocytes
(4 and 24 h samples), liver, bone marrow and testicular
cells of male mice following a single administration of
25, 50 or 500 mg  kg−1 by oral gavage. Results of the
comet assay are summarized in Table 1. The cell viability
observed in the trypan blue staining protocol was  over 80%
in all treatments (data not shown), which conﬁrms the
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Table  1
DNA migration in the comet assay for assessing the genotoxicity of 6,7-dihydroxycoumarin (6,7-HC) in different cells of male Swiss mice in vivo (mean ± SD).
Treatments and cells analyzed Totala Comet class Scores
0 1 2 3
Peripheral blood (4 h sample)
Control 14.00 ± 4.43 86.00 ± 4.43 12.17 ± 4.62 1.33 ± 0.52 0.50 ± 0.84 16.33 ± 4.55
6,7-HC 25 mg kg−1 4.17 ± 1.67 95.83 ± 1.67 4.17 ± 1.67 0.00 ± 0.00 0.00 ± 0.00 4.17 ± 1.67
6,7-HC 50 mg  kg−1 5.33 ± 1.60 94.67 ± 1.60 5.33 ± 1.60 0.00 ± 0.00 0.00 ± 0.00 5.33 ± 1.60
6,7-HC 500 mg  kg−1 6.17 ± 2.67 93.83 ± 2.67 6.00 ± 2.38 0.17 ± 0.37 0.00 ± 0.00 6.33 ± 2.98
Doxorubicin 80 mg  kg−1 30.00 ± 3.42* 72.17 ± 6.94 23.83 ± 2.54 5.00 ± 1.15 1.17 ± 0.37 37.33 ± 4.64*
Peripheral blood (24 h sample)
Control 12.33 ± 3.27 87.67 ± 3.27 11.50 ± 3.56 0.83 ± 0.75 0.00 ± 0.00 17.17 ± 3.13
6,7-HC 25 mg kg−1 17.00 ± 3.27 83.00 ± 3.27 15.00 ± 2.77 2.00 ± 0.58 0.00 ± 0.00 19.00 ± 3.79
6,7-HC 50 mg  kg−1 16.50 ± 2.22 83.50 ± 2.22 14.00 ± 1.91 2.50 ± 0.50 0.00 ± 0.00 19.00 ± 2.58
6,7-HC 500 mg  kg−1 17.00 ± 2.08 83.00 ± 2.08 14.67 ± 1.80 2.33 ± 0.75 0.00 ± 0.00 19.33 ± 2.56
Doxorubicin 80 mg  kg−1 36.00 ± 4.43* 64.00 ± 4.43 25.50 ± 6.24 8.50 ± 1.71 2.00 ± 0.82 48.50 ± 3.59*
Liver
Control 33.17 ± 4.36 66.83 ± 4.36 32.33 ± 4.08 083 ± 0.98 0.00 ± 0.00 34.00 ± 4.82
6,7-HC 25 mg kg−1 21.33 ± 4.19 78.67 ± 4.19 21.17 ± 3.98 0.17 ± 0.37 0.00 ± 0.00 21.50 ± 4.43
6,7-HC 50 mg  kg−1 23.67 ± 3.30 76.33 ± 3.30 22.17 ± 2.61 1.50 ± 0.76 0.00 ± 0.00 25.17 ± 4.02
6,7-HC 500 mg  kg−1 27.83 ± 2.73 72.17 ± 2.73 26.33 ± 1.97 1.50 ± 1.12 0.00 ± 0.00 29.33 ± 3.68
Doxorubicin 80 mg  kg−1 88.67 ± 3.14* 11.33 ± 3.14 44.83 ± 2.03 30.33 ± 1.97 13.50 ± 1.38 149.00 ± 7.19*
Bone marrow
Control 21.67 ± 5.54 78.83 ± 5.54 21.33 ± 5.05 0.33 ± 0.82 0.00 ± 0.00 22.00 ± 6.10
6,7-HC 25 mg kg−1 12.83 ± 2.48 87.17 ± 2.48 12.50 ± 2.22 0.33 ± 0.47 0.00 ± 0.00 13.17 ± 2.79
6,7-HC 50 mg  kg−1 12.17 ± 1.34 87.83 ± 1.34 11.17 ± 0.69 1.00 ± 1.00 0.00 ± 0.00 13.17 ± 2.27
6,7-HC 500 mg  kg−1 12.33 ± 1.80 87.67 ± 1.80 11.83 ± 1.57 0.50 ± 0.50 0.00 ± 0.00 12.83 ± 2.11
Doxorubicin 80 mg  kg−1 90.67 ± 0.94* 9.33 ± 0.94 35.00 ± 1.73 48.50 ± 1.71 7.17 ± 1.07 153.50 ± 1.98*
Testicular
Control 27.00 ± 6.93 73.00 ± 6.93 24.50 ± 6.63 2.33 ± 2.42 0.17 ± 0.41 29.67 ± 8.43
6,7-HC 25 mg kg−1 6.33 ± 2.21 93.67 ± 2.21 5.83 ± 1.77 0.50 ± 0.50 0.00 ± 0.00 6.83 ± 2.67
6,7-HC 50 mg  kg−1 10.33 ± 1.89 89.67 ± 1.89 10.33 ± 1.89 0.00 ± 0.00 0.00 ± 0.00 10.33 ± 1.89
6,7-HC 500 mg  kg−1 13.17 ± 2.61 86.83 ± 2.61 13.17 ± 2.61 0.00 ± 0.00 0.00 ± 0.00 13.17 ± 2.61
Doxorubicin 80 mg  kg−1 40.83 ± 4.56* 60.83 ± 4.18 29.33 ± 2.56 9.00 ± 1.53 2.50 ± 0.76 54.83 ± 7.43*
a
i
D
n
a
v
d
t
o
w
t
f
1
D
p
T
o
e
w
o
m
t
o
aa Total number of damaged cells (class 1 + 2 + 3).
* Signiﬁcantly different from the negative control (P < 0.05).
bsence of cytotoxicity found by PCE/NCE ratio analysis
n the micronucleus (MN) test (Table 3). As expected,
XR induced a signiﬁcant increase (P < 0.001) in the total
umber of cells with damage and scores for all cell types
nalyzed in comparison with sunﬂower control, clearly
alidating the species selected and the study design to
etect genotoxic effects. No signiﬁcant increases in the
otal number of cells with DNA damage and scores were
bserved in all cell types over the tested dose range. There
as no statistical difference in DNA migration between
he three tested doses of 6,7-HC in each cell type. In the
ew cells that presented DNA damage, it was minor (class
), as was also observed in the sunﬂower control.
The potential chemoprotection of 6,7-HC against DXR
NA damage administered simultaneously to the test com-
ound was also investigated by the comet assay (Table 2).
he results showed a signiﬁcant reduction in the extent
f DNA damage for peripheral blood and testicular cells
xposed to 25 mg  kg−1 of 6,7-HC plus DXR, when compared
ith the DXR-treated group alone. In the other high doses
f all cell types and in all doses tested in liver and bone
arrow cells, the chemoprevention was not observed. Inhe cells with signiﬁcant chemoprevention, the percentage
f reductions was high and ranged from 80.91% to 87.50%.
The clastogenicity/aneugenicity of 6,7-HC was  evalu-
ted by the micronucleus test. The frequency of MNPCEin bone marrow cells collected 24 and 48 h after the
administration of the test substance and the PCE/NCE
ratio are presented in Table 3. The number of micronu-
cleated cells did not increase after treatment with 25, 50
and 500 mg  kg−1 b.w. of 6,7-HC, demonstrating that this
coumarin derivative has no effects on these mutagenic end-
points at the tested doses. As expected, the administration
of DXR as positive control drug led to a signiﬁcant increase
in the number of micronucleated cells when compared to
the control (P < 0.001). Bone marrow cytotoxicity was eval-
uated by quantifying the PCE/NCE ratio in 200 erythrocytes.
The results revealed that 6,7-HC or DXR treatment did not
decrease the PCE/NCE ratio compared with sunﬂower oil
control.
4. Discussion
To improve the protection and safety of humans and
the environment, international agencies determine the
requirement of in vivo mammalian studies to assess the
genotoxicity of chemicals intended for human use to its
registration and authorization as therapeutic agents [35].
On the other hand, other international agencies, as the
European Commission Cosmetic Products Directive, deter-
mine an increase in efforts to reduce the use of animals in
safety testing. To address both goals, in the present study
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Table 2
DNA migration in the comet assay for assessing the antigenotoxicity of 6,7-dihydroxycoumarin (6,7-HC) in different cells of male Swiss mice in vivo
(mean  ± SD).
Treatments and cells analyzed Totala Comet class Scores Reduction
(%)b
0 1 2 3
Peripheral blood (4 h sample)
6,7-HC 25 mg  kg−1+ DXR 80 mg kg−1 13.00 ± 2.38* 87.00 ± 2.38 11.50 ± 1.71 1.50 ± 0.76 0.00 ± 0.00 14.50 ± 3.10* 80.91
6,7-HC 50 mg  kg−1 + DXR 80 mg  kg−1 28.17 ± 3.24 71.83 ± 3.24 22.67 ± 2.49 5.00 ± 0.58 0.50 ± 0.50 34.17 ± 4.49 9.87
6,7-HC 500 mg  kg−1 + DXR 80 mg  kg−1 28.33 ± 3.50 71.67 ± 3.50 22.67 ± 2.49 5.17 ± 0.69 0.50 ± 0.50 34.50 ± 4.99 9.12
Doxorubicin (DXR) 80 mg kg−1 30.00 ± 3.42 72.17 ± 6.94 23.83 ± 2.54 5.00 ± 1.15 1.17 ± 0.37 37.33 ± 4.64
Peripheral blood (24 h sample)
6,7-HC 25 mg  kg−1+ DXR 80 mg kg−1 18.17 ± 2.85* 81.83 ± 2.85 15.33 ± 2.21 2.17 ± 0.69 0.67 ± 0.47 21.67 ± 3.99* 85.63
6,7-HC 50 mg  kg−1 + DXR 80 mg  kg−1 34.17 ± 2.54 65.83 ± 2.54 29.00 ± 2.00 4.00 ± 0.82 1.17 ± 0.37 40.50 ± 3.30 27.11
6,7-HC 500 mg  kg−1 + DXR 80 mg  kg−1 32.67 ± 2.43 67.33 ± 2.43 27.00 ± 1.29 4.00 ± 1.00 1.67 ± 0.75 40.00 ± 4.73 29.13
Doxorubicin (DXR) 80 mg kg−1 36.00 ± 4.43 64.00 ± 4.43 25.50 ± 6.24 8.50 ± 1.71 2.00 ± 0.82 48.50 ± 3.59
Liver
6,7-HC 25 mg  kg−1+ DXR 80 mg kg−1 88.33 ± 1.34 11.17 ± 1.34 47.33 ± 2.75 29.33 ± 1.25 12.17 ± 0.69 142.50 ± 1.98 5.09
6,7-HC 50 mg  kg−1 + DXR 80 mg  kg−1 88.67 ± 2.43 11.33 ± 2.43 47.17 ± 2.41 29.33 ± 2.49 12.17 ± 2.91 142.33 ± 3.59 5.38
6,7-HC 500 mg  kg−1 + DXR 80 mg  kg−1 89.67 ± 1.89 10.33 ± 1.89 50.17 ± 1.95 27.33 ± 1.60 12.17 ± 1.77 141.33 ± 6.47 6.40
Doxorubicin (DXR) 80 mg kg−1 88.67 ± 3.14 11.33 ± 3.14 44.83 ± 2.03 30.33 ± 1.97 13.50 ± 1.38 149.00 ± 7.19
Bone  marrow
6,7-HC 25 mg  kg−1+ DXR 80 mg kg−1 87.67 ± 1.37 12.33 ± 1.37 39.17 ± 3.53 42.50 ± 1.89 6.00 ± 0.82 142.17 ± 2.41 8.07
6,7-HC 50 mg  kg−1 + DXR 80 mg  kg−1 90.83 ± 1.34 9.17 ± 1.34 35.83 ± 1.86 47.17 ± 1.77 7.83 ± 0.69 153.67 ± 2.21 0.12
6,7-HC 500 mg  kg−1 + DXR 80 mg  kg−1 88.67 ± 1.60 10.83 ± 1.77 35.17 ± 2.67 45.50 ± 2.43 8.00 ± 1.29 150.17 ± 3.48 2.36
Doxorubicin (DXR) 80 mg kg−1 90.67 ± 0.94 9.33 ± 0.94 35.00 ± 1.73 48.50 ± 1.71 7.17 ± 1.07 153.50 ± 1.98
Testicular
6,7-HC 25 mg  kg−1+ DXR 80 mg kg−1 11.67 ± 2.81* 88.33 ± 2.81 10.50 ± 2.22 1.17 ± 0.69 0.00 ± 0.00 12.83 ± 3.44* 87.50
6,7-HC 50 mg  kg−1 + DXR 80 mg  kg−1 37.33 ± 2.43 62.67 ± 2.43 28.83 ± 1.77 6.00 ± 1.29 2.50 ± 0.50 48.33 ± 3.90 14.60
6,7-HC 500 mg  kg−1 + DXR 80 mg  kg−1 39.50 ± 5.19 60.50 ± 5.19 29.50 ± 2.36 7.83 ± 2.27 2.17 ± 0.69 51.67 ± 8.77 7.58
Doxorubicin (DXR) 80 mg kg−1 40.83 ± 4.56 60.83 ± 4.18 29.33 ± 2.56 9.00 ± 1.53 2.50 ± 0.76 54.83 ± 7.43
* Signiﬁcantly different from doxorubicin (P < 0.05).
o Watera Total number of damaged cells (class 1 + 2 + 3).
b How much 6,7-HC decreased the genotoxicity of the DXR, according t
we combined the in vivo comet and micronucleus (MN)
assays without need to use additional number of animals.
In both the assays, the endpoints measured are differ-
ent. The alkaline version of the comet assay detects double
and single strand breaks in DNA and maximizes the expres-
sion of alkali-labile sites (apurinic sites) transforming them
quickly to strand breaks under alkaline condition [36]. In
comparison with other genotoxicity tests, the advantages
of the comet assay include the sensitivity for detecting
Table 3
Number of micronucleated polychromatic erythrocytes (MNPCE) observed 
4-hydroxycoumarin, and respective controls. For each time period (24 and 48 h) 
Treatments Blood collect time Number of MNPCE
M1 M2
Control (sunﬂower oil) 24 h 1 2 
48  h 2 3 
6,7-Dihydroxycoumarin
(25  mg  kg−1)
24 h 5 3 
48  h 2 1 
6,7-Dihydroxycoumarin
(50  mg  kg−1)
24 h 3 3 
48  h 3 1 
6,7-Dihydroxycoumarin
(500  mg kg−1)
24 h 4 4 
48  h 4 4 
Doxorubicin (DXR)
(80 mg  kg−1)
24 h 7 27 
48  h 24 23 
* Signiﬁcantly different from the negative control (P < 0.001).s et al. [34].
low levels of DNA damage, requirement of small number
of cells per sample, its relative low costs, ﬂexibility, easy
application, and the short time to complete a study. In our
present contribution, comet assay performed in periph-
eral blood leukocytes, liver, bone marrow and testicular
cells showed that the test compound 6,7-HC presented
no genotoxic effects in any of the tested doses. Likewise,
Maistro et al. [27] showed preliminarily, with in vitro stud-
ies, also using the comet assay, absence of cytotoxic and
in the bone marrow cells of male (M1–5) Swiss mice treated with
2000 cells were analyzed. SD = standard deviation of the mean.
 per animal MNPCE
mean ± SD
PCE/NCE
mean ± SD
M3 M4 M5
2 1 2 1.60 ± 0.54 1.30 ± 0.12
2 2 1 2.00 ± 0.70 1.35 ± 0.15
5 2 5 4.00 ± 1.41 1.90 ± 0.33
1 1 2 1.60 ± 0.54 1.50 ± 0.25
4 2 2 2.80 ± 0.83 1.60 ± 0.09
1 2 2 1.80 ± 0.83 1.50 ± 0.40
5 5 6 4.80 ± 0.83 1.30 ± 0.20
7 6 7 5.60 ± 1.51 1.35 ± 0.16
28 24 35 24.20 ± 10.43* 1.20 ± 0.20
9 19 18 18.60 ± 5.94* 1.30 ± 0.16
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enotoxic effects of 6,7-HC in human lymphocytes. The
ame authors also observed absence of point mutations
y the Salmonella/microsome test. Therefore, our in vivo
tudy using comet assay conﬁrms the absence of geno-
oxic effects of 6,7-HC. Another coumarin derivative with
hemical structure very similar to the 6,7-HC that had
ts genotoxic and mutagenic potential analyzed was 4-
ethylesculetin (4-ME). In vitro and in vivo studies using
he comet assay also showed absence of genotoxicity and
utagenicity by the Ames test; however, 4-ME showed
reater cytotoxicity at high concentrations than 6,7-HC
26,27].
The other contribution of this study was to investigate
he in vivo aneugenic/clastogenic potential of 6,7-HC by
icronucleus test. This assay detects gross mutations, like
tructural and numerical chromosome aberrations [32,42].
he results obtained for us revealed that 6,7-HC pre-
ented absence of clastogenic/aneugenic effects in bone
arrow cells of mice. These results conﬁrm the in vitro data
btained on human lymphocytes as well as by the Ames
est [27]. Similarly, Fedato and Maistro [26] also observed
hat 4-methylesculetin has no aneugenic/clastogenic effect
n polychromatic erythrocytes from bone marrow of
ice.
Considering that coumarin derivative 6,7-HC displays
 high antioxidant activity with potential use to humans,
he present study also investigated its potential chemo-
rotection on doxorubicin (DXR)-induced DNA damage.
he results obtained showed that only the lower tested
ose of 6,7-HC (25 mg  kg−1) reduced signiﬁcantly the DNA
amage of DXR. This chemoprotection occurred only in
eripheral blood leukocytes and testicular cells detected
y the comet assay. From the antigenotoxic point of
iew, the coumarin derivative 4-ME, that also exerts a
igh antioxidant activity, demonstrated higher protective
ffects against DXR-induced DNA damage than 6,7-HC. All
ested doses of 4-ME showed antigenotoxic effects in all
nalyzed cell types, with chemoprotection ranging from
4.1% to 93.3% in the comet assay, and 54.4% to 65.9% in
he micronucleus test [26].
In conclusion, the results obtained in this investigation
howed that 6,7-dihydroxycoumarin (6,7-HC) adminis-
ered by gavage was not genotoxic in peripheral blood
eukocytes, liver, bone marrow and testicular cells of mice
y the comet assay, and was not clastogenic/aneugenic
n bone marrow cells of mice by the micronucleus test.
hese results along with the ﬁndings from other studies
n 6,7-HC available in the literature attest its safety rela-
ive to damage in the genetic material of mammals. 6,7-HC
lso plays a role in inhibiting the genotoxicity induced by
he antitumoral agent DXR, but the protective effects were
bserved only in a low dose of simultaneous treatment.
herefore, further studies are needed to better understand
he possible antigenotoxic effects of this hydroxycoumarin
erivative.ransparency document
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